Retrospective Study
Copyright ©The Author(s) 2021.
World J Clin Oncol. Nov 24, 2021; 12(11): 1037-1046
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1037
Table 3 Objective response rate, progression-free survival, and overall survival outcomes
Effectiveness outcome
All patients (n = 48)
Papillary RCC (n = 24)
Chromophobe RCC (n = 9)
Response rate (RECIST 1.1), n (%)
Partial responses13 (27.1)6 (25.0)2 (22.2)
Complete responses0 (0.0)0 (0.0)0 (0.0)
Stable disease27 (56.3)14 (58.3)5 (55.5)
Progressions of disease6 (12.5)3 (12.5)1 (11.1)
Not evaluable2 (4.2)1 (4.2)1 (11.1)
Disease control rate40 (83.3)20 (83.3)7 (77.8)
PFS
Median (mo) (95%CI)12.3 (3.6-20.9)--
Rate of patients progression free at 6 mo67.8%--
Rate of patients progression free at 12 mo49.0%--
OS
Median (mo) (95%CI)27.6 (18.3-37.1)--
Rate of patients alive at 12 mo82.7%--
Rate of patients alive at 24 mo62.0%--

  • Citation: Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World J Clin Oncol 2021; 12(11): 1037-1046
  • URL: https://www.wjgnet.com/2218-4333/full/v12/i11/1037.htm
  • DOI: https://dx.doi.org/10.5306/wjco.v12.i11.1037